Shrikumar Ambujakshan Nair
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$6.7MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $6.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 4, 2019 | NIH | SBIR Phase I Development of a multiplex point-of-care assay to identify patients with Venous Thromboembolism | $297K | AFFINERGY, LLC |
| Aug 3, 2019 | NIH | SBIR Phase II Novel technologies for detection of podocytes from preeclamptic patients | $653K | AFFINERGY, LLC |
| Jul 29, 2019 | NIH | SBIR Phase II Point-of-care device to identify patients at risk for preeclampsia | $736K | AFFINERGY, LLC |
| Sep 22, 2018 | NIH | SBIR Phase II Point-of-care device to identify patients at risk for preeclampsia | $85K | AFFINERGY, LLC |
| Sep 21, 2018 | NIH | SBIR Phase II Point-of-care device to identify patients at risk for preeclampsia | $753K | AFFINERGY, LLC |
| Sep 10, 2018 | NIH | SBIR Phase II Novel technologies to remove obscuring blood from fine needle aspiration biopsies | $204K | AFFINERGY, LLC |
| Aug 7, 2018 | NIH | SBIR Phase II Novel technologies for detection of podocytes from preeclamptic patients | $639K | AFFINERGY, LLC |
| Sep 11, 2017 | NIH | SBIR Phase II Novel technologies for detection of podocytes from preeclamptic patients | $708K | AFFINERGY, LLC |
| Aug 30, 2017 | NIH | SBIR Phase I Point-of-care device to identify patients at risk for preeclampsia | $52K | AFFINERGY, LLC |
| Aug 7, 2017 | NIH | SBIR Phase I Point-of-care device to identify patients at risk for preeclampsia | $200K | AFFINERGY, LLC |
| May 11, 2017 | NIH | SBIR Phase II Novel technologies to remove obscuring blood from fine needle aspiration biopsies | $697K | AFFINERGY, LLC |
| Sep 22, 2016 | NIH | SBIR Phase I Novel technologies for the detection of podocytes from preeclamptic patients | $300K | AFFINERGY, LLC |
| May 13, 2016 | NIH | SBIR Phase II Novel technologies to remove obscuring blood from fine needle aspiration biopsies | $703K | AFFINERGY, LLC |
| May 14, 2015 | NIH | SBIR Phase II Novel technologies to remove obscuring blood from fine needle aspiration biopsies | $698K | AFFINERGY, LLC |
Peer ranks
Federal funding#163
Awards as PI#65
Patents#505
Companies
- AFFINERGY, LLCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.